This early study on rats and rabbits explored a range of potential site effects of the use of various cannabinoids and combinations. Notably, it concluded that the effects of THC were increased in impact and duration by the presence of CBN; measured by time to sleep, induce catantonia, and its capacity to work as an analgestic (pain reliever).
THC and placebo groups were comparable at baseline. Compared with placebo, THC-treated patients reported improved and enhanced chemosensory perception and food 'tasted better'. Premeal appetite and proportion of calories consumed as protein increased compared with placebo. THC-treated patients reported increased quality of sleep and relaxation. Quality of life scores and total caloric intake increased lead to the conclusion that THC may be useful in the palliation of chemosensory alterations and to improve food enjoyment for cancer patients.
Taste and smell disturbances in patients affected by cancer are very common, but often under-recognized symptoms. If not addressed properly, they may impact nutritional status, food enjoyment, and quality of life. Treatment tools available for clinicians to manage chemosensory alterations are limited and are often based on personal clinical experiences. The aim of this study was to assess current oncological and palliative care literature through a scoping review, in order to identify available treatments for taste and smell alterations in cancer patients. This review examines. A broad variety of treatment options were described including zinc and polaprezinc, radio-protectors, vitamins and supplements, anti-xerostomia agents, active swallowing exercises, nutritional interventions, delta-9-tetrahydrocannabinol, and